Metabolic reprograming shapes neutrophil functions in severe COVID‐19
Rebecca Borella, Sara De Biasi, Annamaria Paolini, Federica Boraldi, Domenico Lo Tartaro, Marco Mattioli, Lucia Fidanza, Anita Neroni, Alfredo Caro‐Maldonado, Marianna Meschiari, Erica Franceschini, Daniela Quaglino, Giovanni Guaraldi, Carlo Bertoldi, Marco Sita, Stefano Busani, Massimo Girardis, Cristina Mussini, Andrea Cossarizza, Lara Gibellini
Abstract
To better understand the mechanisms at the basis of neutrophil functions during SARS-CoV-2, we studied patients with severe COVID-19 pneumonia. They had high blood proportion of degranulated neutrophils and elevated plasma levels of myeloperoxidase (MPO), elastase, and MPO-DNA complexes, which are typical markers of neutrophil extracellular traps (NET). Their neutrophils display dysfunctional mitochondria, defective oxidative burst, increased glycolysis, glycogen accumulation in the cytoplasm, and increase glycogenolysis. Hypoxia-inducible factor 1α (ΗΙF-1α) is stabilized in such cells, and it controls the level of glycogen phosphorylase L (PYGL), a key enzyme in glycogenolysis. Inhibiting PYGL abolishes the ability of neutrophils to produce NET. Patients displayed significant increases of plasma levels of molecules involved in the regulation of neutrophils' function including CCL2, CXCL10, CCL20, IL-18, IL-3, IL-6, G-CSF, GM-CSF, IFN-γ. Our data suggest that metabolic remodelling is vital for the formation of NET and for boosting neutrophil inflammatory response, thus, suggesting that modulating ΗΙF-1α or PYGL could represent a novel approach for innovative therapies.